Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
Year: 2024
Type: article
Study design: Observational Study
Abstract: Background: Adjuvant nivolumab has become a standard treatment for patients with completely resected stage III-IV melanoma following the results of the phase 3 CheckMate 238 trial (CM238)[1]. A previous interim analysis of the AdjuMel study reported the first safety and efficacy data of adjuvant nivolumab in France in a real-world setting[2]. The aim of the present analysis is to provide updated outcomes for this study with 2 years of follow-up.
Source: EJC Skin Cancer
Institutions: Hôpital Lyon Sud, Hôpital Ambroise-Paré, Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Hôpital de la Timone, Centre d'Investigation Clinique de Nantes, Immunologie et Nouveaux Concepts en Immunothérapie, Nantes Université, CHU Dijon Bourgogne, Centre Hospitalier de Boulogne sur Mer, Centre Hospitalier Universitaire de Nantes, Bristol-Myers Squibb (France), Centre Hospitalier Universitaire de Lille
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,200
OpenAlex ID: W4399122571